Catabasis Pharmaceuticals to Present at Upcoming Virtual Investor Conferences
September 08 2020 - 8:00AM
Business Wire
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, today announced that Jill C. Milne,
Ph.D., Chief Executive Officer, plans to present a corporate
overview and provide information about edasalonexent, in Phase 3
development for the treatment of Duchenne muscular dystrophy, at
the following virtual investor conferences this month:
- HC Wainwright 22nd Annual Global Investment Conference on
Monday, September 14th, at 4:00pm EDT
- Cantor Virtual Healthcare Conference on Wednesday, September
16th, at 3:20pm EDT
Catabasis will also be participating in the Oppenheimer Virtual
Fall Healthcare, Life Sciences, & MedTech Summit, which will
take place from September 21st – 23rd, 2020.
Live webcasts of the events can be accessed from the investors
section of www.catabasis.com. Archived replays will also be
available for 30 days following the event.
About Edasalonexent (CAT-1004)
Edasalonexent (CAT-1004) is an investigational oral small
molecule designed to inhibit NF-kB that is being developed as a
potential foundational therapy for all patients affected by DMD,
regardless of their underlying mutation. In DMD the loss of
dystrophin leads to chronic activation of NF-kB, which is a key
driver of skeletal and cardiac muscle disease progression. The
ongoing global Phase 3 PolarisDMD trial is evaluating the efficacy
and safety of edasalonexent for registration purposes.
Edasalonexent is also being evaluated in the GalaxyDMD open-label
extension trial. In the MoveDMD Phase 2 trial and open-label
extension, the Company observed that edasalonexent preserved muscle
function and substantially slowed disease progression compared to
rates of change in a control period, and significantly improved
biomarkers of muscle health and inflammation. The FDA has granted
orphan drug, fast track, and rare pediatric disease designations
and the European Commission has granted orphan medicinal product
designation to edasalonexent for the treatment of DMD. For a
summary of clinical results, please visit www.catabasis.com.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and
life-changing therapies to patients and their families. Our lead
program is edasalonexent, an NF-kB inhibitor in Phase 3 development
for the treatment of Duchenne muscular dystrophy. For more
information on edasalonexent and our Phase 3 PolarisDMD trial,
please visit www.catabasis.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200908005302/en/
Investor relations: Andrea Matthews
investors@catabasis.com
Media: Elizabeth Higgins media@catabasis.com
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Apr 2023 to Apr 2024